SHAREHOLDER ALERT: Weiss Law Investigates Opiant Pharmaceuticals, Inc.

NEW YORK, Nov. 14, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Opiant Pharmaceuticals, Inc. ("Opiant" or the "Company") (NASDAQ: OPNT), in connection with its takeover by Indivior PLC. Under the terms of the merger agreement, shareholders will receive $20.00 cash for each Opiant share, plus up to $8.00 per share in contingent value rights ("CVRs") if revenue milestones are achieved by Opiant's lead asset (OPNT003) in the seven years after the U.S. commercial launch of OPNT003. 

Read more at prnewswire.com